BRAK LABS Peptide research, plainly written

question

Are peptides legal in the US?

The answer has layers, and the layer a compound sits in decides everything. Here is each one, with the statute, regulation or agency document behind it.

Last Reviewed Editorial policy Methodology

United States law takes its positions on particular products rather than on a class of chemistry, so the answer here comes in layers. A small number of peptide drugs hold FDA approval and are prescription medicines. Most of the rest are unapproved new drugs. A separate route runs through pharmacy compounding, and two rule systems outside the statute reach people the statute does not.

This page sets out each layer with the document behind it, in the order that decides which one a given compound is in.

Not medical advice

This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.

Reviewed against editorial standards Updated

The short answer

Which layer a compound sits in is the answer. A handful of peptide drugs hold FDA approval, are prescription-only, and are dispensed by pharmacies, and one of them is a compound this site reviews in full: mecasermin is licensed as INCRELEX under biologics licence application BLA021839 [4]. A second group sits inside cosmetics law rather than drug law: acetyl hexapeptide-8, acetyl octapeptide-3 and, applied to skin under the INCI name copper tripeptide-1, GHK-Cu are listed cosmetic ingredients, and 21 U.S.C. 321(i)(1) defines a cosmetic by what it is intended for, articles applied to the body for cleansing, beautifying, promoting attractiveness, or altering the appearance [12]. The rest of the compounds covered here hold no US approval of any kind, and a product sold with a drug intended use falls under 21 U.S.C. 355(a): no person shall introduce or deliver for introduction into interstate commerce any new drug unless an approved application is in effect for it [1].

A research-use-only label does not move a product out of that position. FDA decides whether something is a drug from its intended use, which 21 CFR 201.128 defines as the objective intent of the persons legally responsible for the labeling, shown by their expressions, the design or composition of the article, or the circumstances surrounding its distribution [2]. On 31 March 2026 the agency issued seven warning letters on that reasoning [3].

Possession and personal use are a different question again, and this page does not answer it. What it does answer is what the federal record says about selling and supplying these compounds, and where the pharmacy-compounding route currently stands.

Layer one: the approved peptide drugs

Peptide drugs with FDA approval exist, and there are more of them than most readers expect. Teriparatide is approved as Forteo for osteoporosis at high fracture risk. Tesamorelin is approved as Egrifta for excess abdominal fat in HIV-associated lipodystrophy. Bremelanotide is approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, an approval granted in June 2019. Setmelanotide is approved as Imcivree for obesity from specific rare genetic causes. Each of these is a prescription medicine, approved for a stated indication, prescribed by a clinician and dispensed by a pharmacy. The full list this site refers to, with the approved indication for each, is on the medical disclaimer, read off Drugs@FDA [4].

Two things follow, and the second is the one that gets lost. An approved peptide drug is lawful to prescribe and dispense within that system. And an approval of one peptide is not evidence about another: a compound does not inherit credibility, or legality, from the class it belongs to. A vial of a nominally identical molecule sold online as research material is not the approved product, has not been through the review that approval represents, and does not share its legal position.

Layer two: unapproved new drugs, which is nearly everything else

For most of the compounds this site covers, no application has been approved under section 505 of the Federal Food, Drug, and Cosmetic Act and no biologics licence has been issued either. Where such a compound is sold with a drug intended use it is an unapproved new drug, and 21 U.S.C. 355(a) is the provision that matters: introducing or delivering one into interstate commerce is prohibited while no approval is in effect [1]. Mecasermin is the exception among the compounds with a full review here [4], and thymosin alpha-1 is a partial one: it is registered as a medicine outside the United States and holds no US approval, which the openFDA query on its own page records.

The cosmetic branch is the other one worth naming, because it is a different statute rather than a softer version of this one. Acetyl hexapeptide-8 and acetyl octapeptide-3 are listed cosmetic ingredients with INCI names, which puts them inside cosmetics law, and a cosmetic needs no approval before it is sold. What decides the category is intended use, not chemistry: 21 U.S.C. 321(i)(1) defines a cosmetic as an article intended for cleansing, beautifying, promoting attractiveness or altering the appearance, and 21 U.S.C. 321(g)(1)(B) defines a drug as an article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease [12]. The same molecule in the same jar moves from one definition to the other on what the seller says it is for, which is the point 21 CFR 201.128 makes one layer down.

GHK-Cu is the compound where that split is visible in one molecule, and its own page opens on it. Applied to skin it is copper tripeptide-1, a listed cosmetic ingredient. In a vial for injection it is an unapproved drug. FDA's 503A treatment follows the same split: the non-injectable routes sit in category 1, the bulk substances under evaluation. They came off that list on 22 April 2026 when the nominations were withdrawn; on 5 May 2026 one nominator clarified that it had meant to withdraw the injectable route only and wished to keep the rest, and FDA records that the substance will be added back. The document carrying that history is the 14 May 2026 revision of the list [13]. Category 1 is an enforcement posture rather than an approval. A sentence about one route is not a sentence about the other.

The research-use-only framing is the part readers ask about most, and the answer is unambiguous in the record. Research use only is a labelling concept from the regulations covering in vitro diagnostic devices, and there is no equivalent exemption in the drug provisions of the Act. Whether a product is a drug turns on intended use, and 21 CFR 201.128 says intended use is shown by the seller's expressions, the design or composition of the article, and the circumstances surrounding distribution [2].

FDA applied exactly that reasoning on 31 March 2026, when it issued seven warning letters resting on intended use established by evidence obtained from the sellers' websites. Five of the seven address the research-use framing directly, stating that despite labelling products for laboratory research purposes only, that evidence established the products were intended to be drugs for human use: numbers 721088, 721600, 721709, 721805 and 721806. The other two, 722215 and 722228, carry no research-use language at all, because the products were sold to consumers outright, and they rest on the same intended-use finding without it. All seven are public in FDA's warning letter database [3].

Nothing on this page should be read as saying that a research-use label makes a purchase, a possession, or a use lawful. It does not.

Layer three: the compounding route, and what July 2026 did not change

Section 503A of the Federal Food, Drug, and Cosmetic Act sets out when a drug compounded by a licensed pharmacist or physician is exempt from new drug approval, from labelling with adequate directions for use, and from current good manufacturing practice. One condition concerns the bulk substance the compounder starts from, and where no monograph exists and the substance is not a component of an approved drug, it has to appear on a list FDA develops by regulation. That is the 503A Bulks List, and FDA set the criteria for it in a final rule published on 19 February 2019 at 84 FR 4696 [5].

Several of the compounds covered here are in FDA's category 2, the list of bulk drug substances that may present significant safety risks. The category 2 entry for CJC-1295 reads that compounded drugs containing it may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and characterization of the active ingredient, that FDA has identified serious adverse events associated with it including increased heart rate and systemic vasodilatory reaction, and that available clinical data are limited. The entry for thymosin alpha-1 states that the safety-related information available is inadequate for the agency to sufficiently understand the extent of any safety issues raised [6].

On 23 and 24 July 2026 FDA's Pharmacy Compounding Advisory Committee met on seven peptides under docket FDA-2025-N-6895, which is the meeting the Federal Register notice announced [7]. Be exact about what is on the record and what is not. FDA has published no vote record: the documents it posted for the meeting were prepared beforehand and none carries a tally. What the contemporaneous accounts of the meeting agree on is the outcome, that the committee voted against FDA's proposal on six of the seven substances.

It was widely reported as a clearance and it was not one. A committee recommendation is advice to FDA, it binds nobody, and a substance reaches the 503A Bulks List by notice and comment rulemaking; as of the review date on this page no such rulemaking had been started for any of the seven. This site's record of that meeting reads it against FDA's own published documents, names the accounts the outcome rests on, and says why the vote tallies circulating are reproduced nowhere here.

What is not in the picture: controlled-substance law

None of the compounds covered on this site is on a federal controlled-substance schedule. That is a genuine difference from the class they are most often confused with. Anabolic steroids are defined at 21 U.S.C. 802(41)(A) as drugs or hormonal substances chemically and pharmacologically related to testosterone, and 21 CFR 1308.13(f) places any substance meeting that definition in Schedule III [8] [9].

The distinction is worth holding onto in both directions. Not being scheduled does not make a compound lawful to sell; layer two is the reason. And being unscheduled means the enforcement that does apply comes through FDA and the Act rather than through the Drug Enforcement Administration. The chemistry and law of that comparison is set out separately.

Rules that are not law and still reach people

Two rule systems sit outside the statute and decide real consequences for the people they cover.

The Department of Defense runs one. Its Operation Supplement Safety ingredient and substance index carries a BPC-157 entry stating that BPC-157 is on the DoD Prohibited Dietary Supplement Ingredients list, with a status label of Prohibited, and its linked article, posted 29 April 2025, states that the compound is an unapproved drug that cannot be legally prescribed or sold over the counter [10]. The negative half of that record matters just as much: checked on 2 August 2026 and rechecked on 8 August 2026, KPV has no OPSS entry and no article. The general rule still reaches it, because OPSS states that service members are prohibited from taking unapproved drugs as ingredients in dietary supplements and KPV is an unapproved drug, but anyone writing that the Department of Defense has banned KPV by name is describing something that is not in the record [10].

Anti-doping is the other. The 2026 Prohibited List, effective 1 January 2026, names BPC-157 on the face of its S0 class, names Thymosin-ß4 and its derivatives with TB-500 as an example at S2.3, and names CJC-1295, sermorelin, tesamorelin, ipamorelin and ibutamoren at S2.2.4 [11]. Anti-doping status is decided by an athlete's own anti-doping organization against the current list, and that organization is the only body whose answer counts.

Neither of those systems runs through the statutes above, and a compound's position under one says nothing about its position under the other.

What this page does not cover: state law

Everything above is federal drug law, and it is not the whole picture. State law reaches these products as well, and importation is governed separately again.

This page publishes no reading of either, and the reason is the same one that governs anti-doping positions here: the site does not publish a legal position it has not read the document for. Fifty sets of state statutes, their pharmacy-board rules and the customs regulations have not been read for this page, so no page here summarises them or says what they require. Stating the boundary is more useful than a summary nobody checked, and it is what a reader needs in order to know what this page is worth.

This site does not provide legal advice and does not tell a reader what is lawful for them. It reports the regulatory record with dates and document numbers. The rest is a question for a lawyer in the reader's own jurisdiction.

The four positions, and the document behind each

Our takeThe layer a compound sits in is the whole answer, and the research-use label is the one shortcut the record explicitly refuses.

We report what has been documented. We do not prescribe what should be done.

Frequently asked questions

Are peptides legal to buy in the United States?

There is no single answer, because peptide is a chemistry word rather than a legal category. Approved peptide drugs are prescription medicines, and one compound with a full review here is among them: mecasermin, licensed as INCRELEX under BLA021839. Two others are listed cosmetic ingredients and sit inside cosmetics law. The rest hold no US approval, and selling one for human use puts it under 21 U.S.C. 355(a): introducing an unapproved new drug into interstate commerce is prohibited. This site does not tell readers what is lawful for them, and a question about a specific purchase is a question for a lawyer.

Does a research use only label make a sale lawful?

No. Research use only is a labelling concept from the regulations covering in vitro diagnostic devices, and there is no equivalent exemption in the drug provisions of the Federal Food, Drug, and Cosmetic Act. FDA decides whether a product is a drug from its intended use under 21 CFR 201.128. On 31 March 2026 it issued seven warning letters on that basis, and five of them say so of the research-use label directly: website evidence established human intended use despite the products being labelled for laboratory research purposes only.

Did the July 2026 advisory committee vote make these peptides legal?

No. The Pharmacy Compounding Advisory Committee met on seven peptides on 23 and 24 July 2026 under docket FDA-2025-N-6895. FDA has published no vote record for it, and the contemporaneous accounts agree the committee voted against FDA's proposal on six of the seven. Either way a committee recommendation is advice to FDA, it binds nobody, and substances reach that list by notice and comment rulemaking, which had not been started as of the review date on this page. The same substances are in the same legal position they were in before the meeting.

Are peptides controlled substances?

None of the compounds covered on this site is on a federal controlled-substance schedule. Anabolic steroids are, at Schedule III under 21 CFR 1308.13(f). Being unscheduled is a statement about which body of law applies, not a statement that a sale is lawful.

Is it legal for a compounding pharmacy to make these?

It depends on the substance and the route, and the blanket answer people give is wrong in both directions. Compounding from a bulk substance under section 503A requires a monograph, or that the substance be a component of an approved drug, or that the substance appear on the 503A Bulks List. None of the seven peptides from the July 2026 meeting is on that list, and several are in FDA's category 2 of substances that may present significant safety risks. GHK-Cu is different: its non-injectable routes sit in category 1, the substances under evaluation, which is an enforcement posture rather than an approval. Mecasermin is different again, because it is the active ingredient of an approved product and that is one of the statutory alternatives above.

What about state law?

This page covers federal drug law only, and it says so rather than implying it covers more. State law and import regulation reach these products as well, and this site publishes no reading of either, because it has not read those documents. That is a statement about the scope of this page, not a statement about what those laws say.

References

  1. Office of the Law Revision Counsel, US House of Representatives. 21 U.S.C. 355(a): no person shall introduce or deliver for introduction into interstate commerce any new drug, unless an approval of an application filed pursuant to subsection (b) or (j) is effective with respect to such drug. Read from the United States Code on 30 August 2026. United States Code, title 21. 2023. 21 U.S.C. 355
  2. US Government Publishing Office. 21 CFR 201.128, Meaning of intended uses: the words intended uses refer to the objective intent of the persons legally responsible for the labeling of an article, and that intent may be shown by such persons' expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article. Read from the annual Code of Federal Regulations text on 30 August 2026. Code of Federal Regulations, title 21. 2024. 21 CFR 201.128
  3. US Food and Drug Administration. Seven warning letters issued 31 March 2026, each resting on intended use established by evidence obtained from the seller's website. Five address the research-use framing on its face, stating that the products were intended to be drugs for human use despite being labelled for laboratory research purposes only: 721088, 721600, 721709, 721805 and 721806. Two do not, and carry no research-use language at all, because the products were offered to consumers outright: 722215 and 722228. All seven are public in FDA's warning letter database. The five-and-two split was read off the letters themselves on 30 August 2026. FDA warning letters. 2026. FDA warning letter database
  4. US Food and Drug Administration. Drugs@FDA approved drug products. The approved peptide medicines this site refers to include Forteo (teriparatide), Egrifta (tesamorelin), Vyleesi (bremelanotide, approved June 2019) and Imcivree (setmelanotide), each prescription only and approved for a stated indication. The full set with indications is tabulated on this site's medical disclaimer. Mecasermin, the one compound with a full review here that holds a US licence, is INCRELEX under biologics licence application BLA021839, Ipsen Biopharmaceuticals, and its own page records the licensed population. Drugs@FDA. 2026. Drugs@FDA
  5. US Food and Drug Administration. List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act, final rule, published 19 February 2019 at 84 FR 4696. Sets the four evaluation criteria FDA applies to a nominated bulk substance: physical and chemical characterization, safety issues raised by use in compounded products, evidence of effectiveness or lack of effectiveness, and historical use in compounding. Federal Register document 2019-02367, confirmed against the Federal Register API on 30 August 2026 by document number, title, volume and start page. Federal Register, volume 84, page 4696. 2019. 84 FR 4696
  6. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. The category 2 table carries rows for CJC-1295 and for Thymosin-alpha 1 (Ta1). Page content current as of 22 April 2026, fetched with a browser user agent and read on 23 August 2026. FDA human drug compounding. 2026. FDA category 2 list
  7. US Food and Drug Administration. Pharmacy Compounding Advisory Committee; notice of meeting; establishment of a public docket; request for comments. Docket No. FDA-2025-N-6895, for the meeting of 23 and 24 July 2026. It announces the meeting and carries no outcome: every document FDA posted for this meeting was prepared before it, and none contains a vote tally. The outcome stated on this page rests on the contemporaneous accounts named in this site's own record of the meeting, which is linked in the same section. Federal Register, document 2026-07361. 2026. Federal Register notice
  8. Office of the Law Revision Counsel, US House of Representatives. 21 U.S.C. 802(41)(A): the term anabolic steroid means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone), and includes the substances then listed. Read from the United States Code on 30 August 2026. United States Code, title 21. 2023. 21 U.S.C. 802
  9. US Government Publishing Office. 21 CFR 1308.13, Schedule III, paragraph (f): any substance meeting the definition of anabolic steroid as set forth in section 1300.01 of this chapter, including its salts, esters and ethers. Read on 30 August 2026. Code of Federal Regulations, title 21. 2024. 21 CFR 1308.13
  10. US Department of Defense, Operation Supplement Safety. Ingredient and substance index, and the DoD prohibited dietary supplement ingredients list. The BPC-157 entry reads that BPC-157 is on the DoD Prohibited Dietary Supplement Ingredients list, with a status label of Prohibited, and its linked article of 29 April 2025 states the compound is an unapproved drug that cannot be legally prescribed or sold over the counter. Checked for a KPV entry on 2 August 2026 and rechecked 8 August 2026: KPV has no entry and no article. OPSS, Uniformed Services University. 2026. OPSS ingredient index
  11. World Anti-Doping Agency. The 2026 Prohibited List, international standard, valid 1 January 2026. Read from the retained PDF on 30 August 2026: BPC-157 named among the examples of class S0 at page 4; S2.2.4 naming CJC-1295, sermorelin, tesamorelin, ipamorelin and ibutamoren, and S2.3 naming Thymosin-ß4 and its derivatives with TB-500 as an example, both at pages 7 and 8. The URL serves zero bytes to automation and is ledgered in tools/unverified-sources.json. World Anti-Doping Agency. 2026. WADA 2026 Prohibited List
  12. Office of the Law Revision Counsel, US House of Representatives. 21 U.S.C. 321, definitions. Paragraph (i)(1) defines a cosmetic as articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body or any part thereof for cleansing, beautifying, promoting attractiveness, or altering the appearance. Paragraph (g)(1)(B) defines a drug as articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals. Read from the United States Code on 30 August 2026. United States Code, title 21. 2023. 21 U.S.C. 321
  13. US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, document updated 14 May 2026, carrying the category 1 list. GHK-Cu sits in category 1 for its non-injectable routes: FDA records that it was removed on 22 April 2026 because the nominations were withdrawn, that on 5 May 2026 one nominator clarified it intended to withdraw only the injectable route and wished to retain its nomination for the others, and that the substance will be added back. Category 1 is bulk substances under evaluation, and it is an enforcement posture rather than an approval. Read for the GHK-Cu review and reproduced here rather than re-derived. FDA human drug compounding. 2026. FDA 503A category 1 list